Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Side effects associated with ultrarapid cytochrome P450 2D6 genotype among women with early stage breast cancer treated with tamoxifen.

Clinical laboratory - 1 Jan 2012

Rolla R, Vidali M, Meola S, Pollarolo P, Fanello M R, Nicolotti C, Saggia C, Forti L, Agostino F D, Rossi V, Borra G, Stratica F, Alabiso O, Bellomo G

Abstract excerpt

BACKGROUND: The side effects of tamoxifen, a drug widely used for the treatment and the prevention of recurrence in patients with estrogen receptor positive breast cancers (ER+), have been reported in clinical trials, but to date no information is available on their possible association with an i...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Early Diagnosis

Share to Genotype

Share to Oligonucleotide Array Sequence Analysis

Share to Tamoxifen

Source

Identifiers

PMID: 23289191

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23289191-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Side effects associated with ultrarapid cytochrome P450 2D6 genotype among women with early stage breast cancer treated with tamoxifen.PMID 23289191Read ↗

CYP2D6 genotyping and the clinical impact on outcomes in breast cancer tamoxifen-treated patients.Semantic proximity Read ↗

CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.Semantic proximity Read ↗

Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in Thailand.Semantic proximity Read ↗

Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer.Semantic proximity Read ↗

CYP2D6 polymorphisms and the impact on tamoxifen therapy.Semantic proximity Read ↗

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.Semantic proximity Read ↗

<i>CYP2D6</i> Genotyping for Personalized Therapy of Tamoxifen in Indonesian Women with ER+ Breast CancerSemantic proximity Read ↗

Tamoxifen Dose Escalation in CYP2D6 Poor Metabolizer Breast Cancer Patients and Associated Side EffectsSemantic proximity Read ↗

The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients.Semantic proximity Read ↗

CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis.Semantic proximity Read ↗

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics.Semantic proximity Read ↗

CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.